Title
Category
Credits
Event date
Cost
  • Advanced Practice Provider
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Tailored for medical providers, this session led by a physical therapist addresses challenges like speech and swallowing difficulties or pelvic floor issues in gynecological cancer. Explore the pivotal role of physical therapy in survivorship care plans and delve into current research supporting interventions for head and neck, gynecological, breast cancer, and other oncological conditions. Emphasizing interdisciplinary collaboration, we'll discuss the synergy between medical providers and physical therapists in delivering optimal cancer care. Additionally, learn the art of patient education in oncology rehabilitation, empowering medical providers to effectively communicate the role of physical therapy in cancer care.
  • Advanced Practice Provider
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Patients undergoing treatment for cancer utilize many medications that have relevant drug-gene interactions. The use of pharmacogenomic testing can assist with drug selection, drug dosing, and the development of personalized medication monitoring plans. Amber Cipriani, PharmD, BCOP, will describe some common examples of drug-gene interactions relevant to oncology. She will also discuss current efforts to expand the use of pharmacogenomic testing into current clinical practice.
  • Advanced Practice Provider
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Immunotherapy has made tremendous progress as cancer-directed therapy has evolved, particularly in the field of T cell-engaging therapies. Common and serious side effects of these types of therapies include Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Join us as Bejal Kikani, MSN, FNP-BC, WHNP-BC, discusses the recognition, grading, and treatment of these toxicities.
  • Advanced Practice Provider
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Jeremiah 'Jig' Deneve, DO, FACS, provides an overview of the natural history, treatment, and outcome for peritoneal carcinomatosis.
  • Advanced Practice Provider
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Megan McElfresh, PA-C, will review chimeric antigen receptor therapy, associated side effects, and the treatment or prevention of side effects.
  • Advanced Practice Provider
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
This multidisciplinary Panel Presentation will describe the importance of CT-based lung cancer screening, indications and criteria for screening, the optimal structure and requirements of a screening program, and the current state of screening at UNC. We will present practical information relevant to providers who may order screening CT and/or may discuss screening with patients.
  • Advanced Practice Provider
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Allison Phillips, MPAP, MHPE, PA-C, reviews the clinical manifestations, underlying causes, and management of some of the most common emergencies facing patients undergoing cancer treatment, including Superior Vena Cava Syndrome, Hypercalcemia, and SIADH.
  • Advanced Practice Provider
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Robyn Tolley, AGPCNP-BC, will identify cytotoxic vesicant and irritant drugs, evaluation of infiltration and extravasation, recommended non-pharmacologic and pharmacologic treatments, and when care should be advanced to involve plastic surgery. She will also include an evaluation of risk factors and appropriate preventive measures to reduce the risk of extravasation.
  • Advanced Practice Provider
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Attendees will learn about the benefits of exercise during and after cancer treatment, designing programs that provide maximum benefits, and how to engage patients in increasing their physical activity during and after treatment.
  • Advanced Practice Provider
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Clarissa Urban, PA-C, will cover the basics of clinical trials for an APP. She will highlight the different phases of trials, the clinical trial team, and documents pertaining to trials. In addition, she will focus on phase 1 clinical trials along with diversity in trial participation.

Pages